NYSEARCA:THNR Amplify Weight Loss Drug & Treatment ETF (THNR) Price, Holdings, & News $26.14 0.00 (0.00%) Closing price 11/13/2026 04:10 PM EasternExtended Trading$26.12 -0.02 (-0.08%) As of 11/13/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatings About Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get THNR alerts:Sign Up Key Stats Today's Range$25.83▼$26.1450-Day Range$24.03▼$27.0152-Week Range$23.40▼$27.94Volume745 shsAverage Volume1,750 shsMarket Capitalization$5.23 millionAssets Under Management$5.20 millionDividend YieldN/ANet Expense Ratio0.59%Aggregate RatingModerate Buy ETF Overview The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments. Read More Amplify Weight Loss Drug & Treatment ETF ExpensesTypeTHNRTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.59%0.57%0.57%0.50%0.53%Other Expenses0.00%0.57%0.53%0.60%0.54%Total Expense0.59%0.72%0.75%0.75%0.73%Fee Waiver0.00%-0.72%-0.67%-0.76%-0.67%Net Expense0.59%0.60%0.63%0.57%0.60% Receive THNR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Weight Loss Drug & Treatment ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THNR ETF News HeadlinesETFs tied to HIMS gain attention as the telehealth stock spikesMarch 9, 2026 | msn.comHims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFsSeptember 18, 2025 | benzinga.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008. | Weiss Ratings (Ad)Why Investors Haven't Feasted on Two New Weight-Loss ETFsJune 24, 2024 | investopedia.comSee More Headlines THNR ETF - Frequently Asked Questions How have THNR shares performed this year? Amplify Weight Loss Drug & Treatment ETF's stock was trading at $25.22 at the beginning of the year. Since then, THNR shares have increased by 3.6% and is now trading at $26.14. How do I buy shares of Amplify Weight Loss Drug & Treatment ETF? Shares of THNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Fund Details IssuerAmplify Fund NameAmplify Weight Loss Drug & Treatment ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:THNR Inception Date5/21/2024 Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Constituents22 Fund Statistics Assets Under Management$5.20 million Average Daily Volume$0.00 Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments, LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerGTS Miscellaneous Outstanding Shares200,000Beta0.39 Creation Unit10,000 Creation Fee$300.00 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report Top 10 THNR HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 11.93%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 8.69%Amgen (NASDAQ:AMGN)Holding Weight: 6.08%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 6.01%AstraZeneca PLCHolding Weight: 5.77%Gilead Sciences (NASDAQ:GILD)Holding Weight: 5.66%Roche Holding AGHolding Weight: 5.62%AbbVie (NYSE:ABBV)Holding Weight: 5.59%Pfizer (NYSE:PFE)Holding Weight: 5.29%Chugai Pharmaceutical Co., Ltd.Holding Weight: 5.09%Full Holdings DetailsTHNR Sector ExposureTHNR Industry Exposure This page (NYSEARCA:THNR) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredReport: OCC clears Trump-linked bankI told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was. Federal r...Crypto 101 Media | SponsoredGlobal Industrial Powerhouse Taps Nasdaq Drone MicrocapA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.